Contact our breast care nurses
0808 800 6000
Responding to the updated draft guidance from NICE to not recommend Perjeta (pertuzumab) for routine NHS use after surgery for early HER2-positive...
Responding to news that health officials are investigating concerns that adults who should have been invited for breast and bowel cancer screening...
Perjeta, given in combination with Herceptin (trastuzumab) and docetaxel (a chemotherapy drug), is a first-line treatment for patients with HER2-...
Discussing the news that NHS trusts are being encouraged to move away from the breast cancer drug Herceptin to use a biologically similar medicine,...
We have responded to National Cancer Patient Experience Survey showing satisfaction with NHS cancer care is at a record high. ...
The Secretary of State for Health and Social Care, Matt Hancock today outlined his commitments to workforce, technology and prevention, in his first...
Responding to the publication of NICE’s updated guidance for early and locally advanced breast cancer, Samia al Qadhi, Chief Executive of Breast...
Responding to the news that flight attendants are more likely to develop several forms of cancer than the average person, Addie Mitchell, Clinical...
Responding to new evidence from the Institute of Cancer Research suggesting that higher BMIs in young women reduce their risk of breast cancer,...
Stay in touch
We’d love to keep in touch about news, events and how you can get involved. To hear from us, enter your email address below.
Connect with us
